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Abstract
Background: Microbicides must protect against STD pathogens without causing unacceptable toxic effects.
Microbicides based on nonoxynol-9 (N9) and other detergents disrupt sperm, HSV and HIV membranes, and
these agents are effective contraceptives. But paradoxically N9 fails to protect women against HIV and other STD
pathogens, most likely because it causes toxic effects that increase susceptibility. The mouse HSV-2 vaginal
transmission model reported here: (a) Directly tests for toxic effects that increase susceptibility to HSV-2, (b)
Determines in vivo whether a microbicide can protect against HSV-2 transmission without causing toxicities that
increase susceptibility, and (c) Identifies those toxic effects that best correlate with the increased HSV
susceptibility.
Methods: Susceptibility was evaluated in progestin-treated mice by delivering a low-dose viral inoculum (0.1
ID50) at various times after delivering the candidate microbicide to detect whether the candidate increased the
fraction of mice infected. Ten agents were tested – five detergents: nonionic (N9), cationic (benzalkonium
chloride, BZK), anionic (sodium dodecylsulfate, SDS), the pair of detergents in C31G (C14AO and C16B); one
surface active agent (chlorhexidine); two non-detergents (BufferGel®, and sulfonated polystyrene, SPS); and HEC
placebo gel (hydroxyethylcellulose). Toxic effects were evaluated by histology, uptake of a 'dead cell' dye,
colposcopy, enumeration of vaginal macrophages, and measurement of inflammatory cytokines.
Results: A single dose of N9 protected against HSV-2 for a few minutes but then rapidly increased susceptibility,
which reached maximum at 12 hours. When applied at the minimal concentration needed for brief partial
protection, all five detergents caused a subsequent increase in susceptibility at 12 hours of ~20–30-fold.
Surprisingly, colposcopy failed to detect visible signs of the N9 toxic effect that increased susceptibility at 12
hours. Toxic effects that occurred contemporaneously with increased susceptibility were rapid exfoliation and
re-growth of epithelial cell layers, entry of macrophages into the vaginal lumen, and release of one or more
inflammatory cytokines (Il-1β, KC, MIP 1α, RANTES). The non-detergent microbicides and HEC placebo caused
no significant increase in susceptibility or toxic effects.
Conclusion: This mouse HSV-2 model provides a sensitive method to detect microbicide-induced toxicities that
increase susceptibility to infection. In this model, there was no concentration at which detergents provided
protection without significantly increasing susceptibility.
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Background
The healthy, intact vaginal epithelium provides a signifi-
cant barrier against infection: To transmit infection relia-
bly, 10,000 times more SIV must be delivered to the
macaque vagina than that required intravenously [1], and
in humans, heterosexual transmission of HIV is estimated
to occur in only ~1/1000 coital acts [2]. Even when the
male partner is in the highly infectious acute phase, trans-
mission is estimated to occur in only ~1/50 coital acts [3].
Thus any microbicide that has a toxic effect that compro-
mises the vaginal barrier can cause a major increase in sus-
ceptibility. To help identify promising microbicide
candidates for future efficacy trials, preclinical screening
tests are needed that will disclose any toxic effect that
increases vaginal susceptibility to infection. At present,
screening for toxic effects in vivo is most often performed
in the primate, rabbit, and mouse vaginal irritation mod-
els [4-9]. These models employ histology, colposcopy,
and the release of inflammatory cytokines to detect toxic
effects [4-6,8-12]. Although of obvious importance, these
toxic effects serve only as surrogates for susceptibility, and
thus they may fail to disclose toxic effects that significantly
increase susceptibility to infection. Fortunately, animal
models can be devised to test directly whether a microbi-
cide increases susceptibility.
Some readily observed toxic effects are very likely to
increase susceptibility, such as ulceration and inflamma-
tory conditions that increase access to target cells, but
there may also be additional susceptibility-increasing
toxic effects that have not yet been identified or observed;
for example, toxic effects that increase the density of cell-
surface receptors on target cells, or that increase the ampli-
fication of nascent infections. With this in mind, we devel-
oped a mouse vaginal model to detect whether candidate
microbicides cause, by any mechanism, toxicity that
increases the susceptibility of the vagina to HSV infec-
tions. HSV-2, like HIV, is an enveloped virus that can
transmit infections through the epithelium, and genital
herpes is a major STI that is a major co-factor for HIV
transmission [13]. HSV-2 is a human pathogen that read-
ily infects many other species, including mice, by binding
to highly conserved entry receptors, especially nectin-1,
on epithelial target cell surfaces. For example, human,
bovine, and porcine herpes viruses can all use human,
mouse and porcine forms of nectin-1 for cell entry [14].
Moreover, the course of infection is similar in mice and
humans. These characteristics strongly suggest that candi-
date microbicides that increase HSV susceptibility in mice
will likely increase HSV susceptibility in humans.
HIV and HSV both bind initially to heparan sulphate-like
molecules on the surfaces of their target cells [15], and
although these viruses then use different entry receptors,
toxic effects that increase the presence of, or access to,
heparan sulphate receptors on their target cells might pos-
sibly increase susceptibility to both viruses. Similarly, sul-
fonated and sulfated polysaccharides (PRO 2000, SPS,
cellulose sulphate, carrageenan), bind to both viruses, and
PRO 2000 protects against both HIV [16] and HSV [17] in
animal models and against both HIV and HSV in human
ex vivo tests [18]. Thus toxic effects that increase HSV sus-
ceptibility in the mouse may in some cases also reveal
toxic effects that increase HIV susceptibility [19].
A key paper by Phillips and Zacharopoulus [20] on sus-
ceptibility to rectal transmission of HSV in the mouse
revealed that nonoxynol-9 (N9) not only failed to protect,
but caused rapid exfoliation of sheets of epithelial cells
and greatly increased rectal susceptibility. Phillips and
colleagues then found [21,22] that N9 causes similar
rapid exfoliation of rectal epithelium in humans. Their
results strongly suggest that N9 should not be used for rec-
tal protection in humans. In testing microbicides for pro-
tective efficacy in a mouse chlamydia model [23], we
found that chlorhexidine (CHX), a widely used microbi-
cidal preservative, causes a 100-fold increase in vaginal
susceptibility to Chlamydia trachomatis when tested three
days after a single vaginal application of this surface-active
agent. Thus mouse models for vaginal transmission of
HSV and chlamydia provide a way to detect in vivo toxicity
that increases vaginal susceptibility to viral as well as bac-
terial STD pathogens. The protective efficacy of many can-
didate microbicides has been tested for HSV and
Chlamydia in a variety of mouse models [7,24-28]. The
present investigation is the first designed to: (a) Detect
susceptibility-increasing toxicities by observing suscepti-
bility as a function of time following a single application
of candidate microbicides, (b) Test whether there is a dose
range of a candidate microbicide that can prevent vaginal
HSV transmission without causing toxicities that increase
susceptibility to HSV, and (c) Monitor observable toxic
effects that could potentially be used in clinical (Phase I)
evaluations of candidate microbicides to identify toxic
effects that best correlate with toxicities that increase vag-
inal susceptibility to HSV.
Methods
Microbicide candidates
A cross-section of candidate microbicides was selected,
some of which have been reported to protect against HSV-
2 in mouse vaginal transmission models: N9 [28], SPS
[26] (which is similar to T-PSS [24]), chlorhexidine [26],
and BufferGel [29]. Others were selected based on pub-
lished in vitro tests: C31G inactivates HSV-2 [30] and both
detergents in C31G, (C14AO+C16B), inactivate HIV [4,31];
BZK and SDS both inactivate HIV [10,31]. Several deter-
gents were selected since detergents, especially N9, are the
candidates for which the most clinical data are available.
All five of the detergents are comparably potent at inacti-BMC Infectious Diseases 2006, 6:90 http://www.biomedcentral.com/1471-2334/6/90
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vating HSV, HIV, or sperm in vitro: ~0.01–0.03% rapidly
disrupts envelope and cell membranes [4,32-34]. Nonox-
ynol-9 is a non-ionic detergent used in most currently
available vaginal spermicides and detergent-coated con-
doms, and is widely used in disinfectant handwashes.
Benzalkonium Chloride (BZK) is a cationic detergent with
exceptionally broad microbicidal action and is a compo-
nent of the "Protectaid®" contraceptive sponge. Sodium
Dodecyl Sulfate (SDS, also called sodium lauryl sulfate,
SLS) is an anionic detergent widely used in toothpastes,
shampoos and shaving creams. C31G is an equimolar
mixture of two detergents (C14AO, C14 alkyl amine oxide
and C16B, C16 alkyl betaine) used as an oral disinfectant
in dentistry and as the active ingredient in "Savvy", a sper-
micidal microbicide now in clinical efficacy trials for con-
traception and HIV prevention. Chlorhexidine (CHX) is a
surface active agent that is even more potent than the
above detergents and is used as a preservative in K-Y Jelly®
and Surgilube®, and as a disinfectant in mouthwashes and
antimicrobial handwashes. BufferGel® is a spermicidal
microbicidal gel made with Carbopol 974P, a cross-linked
polyacrylic acid polymer, and formulated at pH 3.9 to
match the pH of the healthy human vagina. It has ade-
quate buffer capacity to acidify the ejaculate and thereby
reinforces the protective acidity of the vagina. Sulfonated
polystyrene (SPS) is a polymer similar to T-PSS [24], and
has potent spermicidal and antiviral efficacy in vitro [26].
It is similar, to some extent, to the sulfated and sulfonated
polysaccharides now in clinical HIV prevention trials
(Carraguard, PRO 2000, and cellulose sulphate). These
candidates were obtained from: N9 (Rhone-Poulenc,
Cranbury NJ); BZK and chlorhexidine (Sigma, St. Louis,
MO); SDS (Invitrogen Corp., Carlsbad, CA); C14AO (myr-
istyl dimethylamine oxide, Chemron, Pasa Robles, CA.)
and C16B (cetyldimethylbetaine, DeForest Enterprises,
Inc., Boca Raton, FL); BufferGel® and HEC placebo gel
[35] (ReProtect, Inc., Baltimore MD); SPS (polystyrene
sulfonate, average molecular weight 500,000: Scientific
Polymer Products, Inc., Ontario, NY). With the exception
of BufferGel and the HEC placebo gel, all agents were
tested for toxicity as 2% solutions in phosphate buffered
saline (PBS) to avoid the confounding effects of differing
formulations. Similarly, for determining the acute toxicity
and protective efficacy, the detergents and CHX were also
delivered in PBS but at various concentrations as needed.
Mouse model
Progestin treatment
Female CF-1 mice 6–8 weeks old (Harlan, Indianapolis,
IN) were acclimatized for 1–2 weeks after shipping, then
injected subcutaneously with 2.5 mg Depo-Provera®
(medroxyprogesterone acetate) (Pharmacia & Upjohn
Company, Kalamazoo, MI.), a treatment that produces a
diestrous-like state that eliminates the stratified squamous
layer of dead and dying cells that otherwise helps protect
the vagina. In this diestrous-like state the epithelium
becomes similar to columnar epithelium in that the entire
epithelial surface becomes covered with living cells. This
progestin treatment greatly increases HSV susceptibility
and makes mice more uniform in susceptibility than ran-
domly cycling mice [26,28,36]. Depo-Provera makes the
mouse vagina more closely mimic the most accessible
HSV target cells in the human female genital tract, the
columnar epithelial cells of the endocervical canal and
regions of cervical ectopy that occur commonly in
younger women, regions in which living cells are exposed
directly on the face of the cervix.
Viral inoculum
Strain G of HSV-2 (ATCC lot #3405329) was obtained
from Virotech International (Rockville, MD; 5 × 108
TCID50/ml). The viral stock was thawed and refrozen in
100 μl aliquots, then stored at -70°C. A thawed aliquot of
viral stock was diluted with Bartels Tissue Culture Refeed-
ing Medium (Trinity Biotech, St. Louis, MO) to yield an
inoculum with 10 ID50  in a 10 μl inoculum (~104
TCID50). For low-dose inocula, the viral stock was further
diluted with Bartels Medium as needed. The diluted viral
stock was stored on ice and used within 1 hour of thaw-
ing. The 10 μl viral inoculum was delivered with a Wiret-
rol pipet (Drummond Scientific, Broomall, PA) with a
fire-polished tip to minimize potential injury.
Assay for infection
As reported earlier [26,28,29], vaginal lavages were
obtained 3 days after inoculation and evaluated for viral
shedding. Input virus from the inoculum can not be
detected for more than 6 hours after the inoculation, and
viral shedding by infected animals reaches a maximum at
3 days (data not shown). This assay is more rapid and also
more sensitive than waiting for visible lesions or death
[26], both of which are more dependent on the hormonal
and immune status of the mouse [37]. Importantly, assay
of infection at day 3 avoids causing animal pain. Fifty μl
of Bartels Medium was delivered to the vagina and pipet-
ted in and out 20 times to maximize viral recovery, then
diluted into 50 μl Bartels Medium in a 0.5 ml microfuge
tube. The vaginal lavage samples were then spun at 6500
rpm for 5 minutes to pellet the cells and mucus. The pellet
was then removed using a pipet tip to draw the pellet up
the side of the tube and out of the supernatant. The super-
natant was then placed on target cells (human newborn
foreskin diploid fibroblast cells; Biowhitaker, Walkers-
ville, MD). Cytopathic effect was scored 48 hours later,
and mice whose lavage cultures displayed cytopathic
effect were considered infected. The entire test thus
requires a total of 5 days from inoculation to assay of
infection, making this a relatively rapid and efficient ani-
mal model.BMC Infectious Diseases 2006, 6:90 http://www.biomedcentral.com/1471-2334/6/90
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Protection assay
Two procedures were used to observe the protective effi-
cacy of the test agents. In the "mix externally" procedure,
the 10 μl viral inoculum with 10 ID50 was mixed together
with 20 μl of the test agent, incubated for 5 minutes at
37°C, and then this mixture was delivered to the vagina
using a 50 μl Wiretrol pipet with fire polished tip. This
method insures the virus is fully exposed to the test agent
before it can contact target cells. In the "mix in vagina"
procedure, which is intended to mimic human use of a
microbicide, 20 μl of the test agent (or PBS) was delivered
to the vagina and the 10 μl viral inoculum with 10 ID50
was delivered after a specified time interval. In most exper-
iments 30 mice were divided into groups of 10, one group
treated with one test agent, a second group with a second
test agent, and the third (control) group was treated with
PBS (phosphate buffered saline). Each such experiment
was repeated two or three times to obtain results from 20
to 30 mice for each test agent.
Susceptibility assay
In this procedure, 20 μl of the test agent was delivered to
the vagina, and then a low-dose inoculum with 0.1 ID50
was delivered in 10 μl of Bartels medium after a specified
time interval. To determine the relative susceptibility of
the mice, two groups of control mice (treated with PBS at
the same time interval) were used, one group inoculated
with the same 0.1 ID50 low-dose inoculum and one inoc-
ulated with 10 ID50. On average, the low-dose inoculum
infected 13.5% of the control mice; the high-dose inocu-
lum infected 87%. For each test agent, the fraction
infected in each of its control groups was used to construct
a dose-response graph (fraction infected vs log ID) and
drawing a linear interpolation between the fractions
infected by the 0.1 and 10 ID50 inoculations. The fraction
of mice infected in the test group was then plotted on this
graph to determine the effective ID of the low-dose inoc-
ulum. Relative susceptibility is defined as the ratio of the
effective ID the low-dose inoculum delivered to the test
mice divided by the ID it delivered to control animals. For
example, if the low-dose 0.1 ID50 inoculum infected 50%
of the test mice, it acted effectively as 1 ID50 indicating the
relative susceptibility of the test mice increased 10 fold. In
most experiments 30 mice were divided into 3 groups of
8 (two test groups and 1 control group) all of which
received the low-dose 0.1 ID50 inoculum, and one control
group of 6 received the high-dose10 ID50 inoculum. Each
experiment was repeated to obtain ~30–50 mice per
group to insure robust statistical power.
Acute toxicity
Dead cell dye
To detect acute toxicity to the epithelial cells, the vagina
was stained with YOYO®-1 (Molecular Probes, Inc.,
Eugene, OR) a membrane impermeant dye that can enter
the nuclei, and thereby become highly fluorescent, in cells
whose membranes are disrupted. To keep the mice immo-
bile throughout this test procedure, they were first anes-
thetized by intraperitoneal injection of 0.5 ml "Avertin"
(2.5 g 2,2,2 tribromoethanol in 5 ml amylene hydrate and
200 ml water). Fifty μl of the test agent (or PBS control)
was delivered with a Wiretrol pipet with fire-polished tip,
and the agent left in place for 10 minutes. The vagina was
then gently lavaged for 10 minutes using a syringe pump
to continuously deliver PBS through a fire-polished Wiret-
rol pipet at a rate of 5 ml/minute. Then 20 μl of YOYO-1
(diluted to 5 μM with PBS) was delivered and left in place
for 10 minutes before again lavaging the vagina for 10
minutes with PBS to remove unbound dye. The mouse
was then sacrificed, the vagina dissected out and slit open
lengthwise, and again rinsed for 10 minutes in PBS. The
entire vagina was then mounted between two microscope
slides that were squeezed together to flatten the vagina
and open its numerous folds (rugae). Digital images of
the flat-mounted vagina were taken with a macro-lens
(1×) in a Nikon E800 epifluorescence microscope.
Histology
Groups of 4 mice were treated intra-vaginally with 20 μl
2% N-9 (or PBS for controls) and sacrificed at various
times immediately before dissecting out the vagina. One
N9 group and one control group were dissected at 10 min-
utes, and additional N9 groups were dissected 2, 8, 12, 18,
and 24 hours post-exposure. Each vagina was fixed in 5 ml
10% neutral-buffered formalin (Sigma-Aldrich, St. Louis,
MO). The vaginas were embedded, sectioned transversely
at four regions, stained with hemotoxylin and eosin,
examined by bright-field microscopy, and evaluated for
average number of cell layers in the epithelium, and
scored semi-quantitatively for quantity of visible cellular
material in the lumen.
Cytokine assay
The Bio-Plex system (Bio-Rad, Hercules, CA) was used to
measure mouse inflammatory cytokine concentrations in
vaginal lavage samples. Inflammatory cytokines included
in this study were those shown to be informative in
human vaginal microbicide studies [38] and for which
there were mouse cytokine reagents available for the Bio-
Plex assay. Those tested were: IL-1α, IL-1β, Il-6, KC
(murine equivalent of IL-8), MIP-1α, and RANTES. The
vagina was lavaged repeatedly (pipetted in and out 20
times) with 50 μl PBS. The lavage fluid was then centri-
fuged, as described above, to obtain the supernatant
which was frozen immediately and stored at -70°C until
analyzed. Samples were diluted 1:3 with PBS prior to
assay. Cytokine concentrations were determined using the
calibration procedure and cytokine reference standards
supplied with the Bio-Plex assay. Interference control tests
were performed by spiking ten-fold serial dilutions of 2%BMC Infectious Diseases 2006, 6:90 http://www.biomedcentral.com/1471-2334/6/90
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Vaginal HSV-2 susceptibility and toxic effects vs time after a single dose of 2% N9 Figure 1
Vaginal HSV-2 susceptibility and toxic effects vs time after a single dose of 2% N9. A. Relative susceptibility is the 
effective Infectious Doses the inoculum delivers in N9-exposed mice normalized to the Infectious Doses it delivers in control 
(PBS) mice. The single dose of N9 produced three successive phases in susceptibility, a brief initial protective phase (reduced 
susceptibility) followed by two distinct phases of markedly increased susceptibility. P values were determined by Fisher's exact 
two-sided test comparing the numbers of animals infected and uninfected in the test animals vs. the corresponding numbers in 
control animals treated only with PBS. B-E. Error bars indicate standard deviations around the mean. Concentrations of 
inflammatory cytokines are indicated by geometric means normalized with respect to those for PBS controls. See legend for 
Fig. 6 for geometric means of PBS controls. B, C. Data obtained from histology sections from four locations distributed along 
the length of the vagina. The score in C is a semi-quantitative evaluation of the amount of visible cellular debris in the vaginal 
lumen. For each point in B and C at 10 min, 2, and 8 hours, P values were <0.001 with respect to PBS control values. (n = 8) 
D. P values for all times points from 6 to 18 hours were <0.001 with respect to PBS control values. (n = 20) D, E. Data 
obtained from vaginal lavage samples.
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microbicide samples with defined amounts of cytokine
standards. SPS was the only microbicide that inhibited
cytokine detection within the concentration range
expected to be found in vaginal samples; detection of KC,
MIP-1alpha and RANTES was inhibited >50% in the pres-
ence of SPS at concentrations ranging from 0.2% to
0.002%.
Colposcopy
Mice were anesthetized with Avertin (as described above),
immobilized with tape on a custom-made platform, and
the vagina was held open by means of two small spring-
loaded forceps acting like a speculum with four blades. A
colposcope (Zeiss OPMI 1-SH) was set at maximum mag-
nification (31×) and focused on the epithelium surround-
ing and including the cervix. Direct visual observations
were made by four observers who were not informed of
the agent to which each mouse had been exposed. In addi-
tion, photographic images were obtained, and digitized
for later analysis. All observations were made with care-
fully controlled standard illumination, and all images
were processed and displayed by identical procedures; no
adjustments of color balance or contrast were made to the
digitized images.
Statistics
GraphPad Instat version 3 (San Diego, CA) was used for
statistical analysis. Fisher's exact two-sided test was used
to analyze numbers of mice infected and uninfected in
test groups vs control groups in the protective efficacy and
susceptibility experiments. The changes at each time point
in the number of cell layers, cellular debris in the lumen,
and number of macrophages in the lumen, were com-
pared with those for PBS controls using the unpaired t-test
for 2-tailed P value. For cytokines, concentrations in the
lavage samples were converted to log10 concentrations,
and compared with those for PBS controls using the
unpaired t-test for 2-tailed P value.
Results
Time course of HSV susceptibility after a single application 
of N9
Panel A in Fig. 1 shows susceptibility to HSV as a function
of time after delivering a single dose of 2% N9. The small
inset shows that immediately after delivery N9 reduced
susceptibility about 6-fold (partial protection), but by 5
minutes the mice were no longer protected since the frac-
tion of mice treated with N9 that became infected was
larger than the fraction of the control mice treated with
PBS. At 15 minutes mice treated with N9 became about 5
times more susceptible than the controls (p = 0.04). Sus-
ceptibility rose to a peak at about 3 hours, then declined
to the baseline susceptibility of PBS controls at 6 hours.
Susceptibility then rose again reaching a major peak at
about 12 hours before declining to baseline at 18 and 24
hours. The decrease in susceptibility at 6 hours suggests
there are two separate phases of increased susceptibility.
Note that at the 12 hour peak, a single dose of N9
increased susceptibility nearly 30-fold (P < 0.001), that is,
to infect 50% of the N9 exposed mice, a viral inoculum
that infects 50% of the control mice would have to be
reduced in viral titer by 30-fold.
Time courses of toxic effects that might correlate with 
increases in susceptibility
N9 caused rapid exfoliation of epithelial cells, as indicated
in Fig 1B by the reduction in number of epithelial cell lay-
ers from 4–5 to 1–2 (a loss of about 3 cell layers) and in
Fig 1C by the rapid increase in cellular debris in the vagi-
nal lumen. The cell layers slowly regenerated and returned
essentially to that of the controls by 18 hours. Note that
the initial rapid rise in susceptibility that started at ~5
minutes and peaked at ~3 hours was contemporaneous
with the exposure of deeper cell layers in the vagina, and
that the subsequent major increase in susceptibility that
started after 6 hours, peaked at 12 hours, and ended prior
to 18 hours was contemporaneous with the duration in
which the layers of cells were regenerating.
N9 also caused a delayed but large influx of macrophages
into the vaginal lumen as detected in vaginal lavage sam-
ples, Fig 1D. The peak macrophage content of the lumen
occurred at about 6–8 hours and somewhat preceded the
major peak in HSV susceptibility. Note also that during
the initial rapid rise in susceptibility no macrophages were
detected in the vaginal lumen, and also that macrophages
persisted in the lumen at a greatly elevated level at 18
hours, when the susceptibility had returned to that of the
controls.
Fig. 1E shows the time course of inflammatory cytokines
recovered in vaginal lavage fluid at the times indicated
(each mouse was lavaged once). No Il-6 was detected at
any time, and Il-1α did not change detectably at any time.
There were non-significant trends towards an immediate
increase of IL-1β and KC (murine equivalent to IL-8) fol-
lowed much later at 18 hours by another non-significant
trend toward an increase in IL-1β. In contrast, RANTES
and MIP-1α both exhibited a delayed and major increase
starting at about 8 hours, peaking at about 12 hours, and
persisting at significantly increased levels at 18 hours (a
time when the susceptibility had returned to normal).
Vaginal HSV susceptibility 12 hours after a single 
application of candidate microbicides
Since the major peak in susceptibility caused by toxic
effects of N9 occurred about 12 hours after delivering this
detergent, the other microbicide candidates were also
tested 12 hours after applying a single dose. The two deter-
gents in C31G, C14AO and C16B, were tested separatelyBMC Infectious Diseases 2006, 6:90 http://www.biomedcentral.com/1471-2334/6/90
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since they have been reported to differ significantly in
their toxic effects [4]. The results are summarized in Fig. 2.
All five detergents (N9, C14AO, C16B, BZK, and SDS)
caused comparable major increases in susceptibility (18–
29 fold; P < 0.001). The susceptibility increases caused by
C14AO and C16B did not differ significantly even though
C16B has been reported to produce a less intense inflam-
matory response than C14A [4]. The surface-active agent,
CHX, caused a smaller but significant 5-fold increase (P <
0.003). In contrast, the small susceptibility changes fol-
lowing exposure to BufferGel, SPS, and the HEC placebo
were not significant. The data on which Fig 2 is based are
listed in Table 1.
A single prior exposure to N9 can abolish its transient 
protective effect
The disappointing results of the clinical trials of N9 prod-
ucts for HIV prevention led to the suggestion that persist-
ent toxic effects might increase susceptibility during coital
events when the product was not used. If this is the major
problem caused by N9 toxicity, then "user failure" is of
crucial importance. However, the present results suggest
an additional possibility, namely that detergent toxicity
may cause such rapid and large increases of susceptibility
that even when used correctly they may fail to protect.
Most N9 products are recommended to be used within 1
hour of application, but as shown in Fig. 1A, N9 signifi-
cantly increased susceptibility within 15 minutes of appli-
cation. A second test of the hypothesis that detergents may
not protect even when used correctly is shown in Fig. 3.
Mice were exposed to a single dose of 2% N9, or PBS, and
then 12 hours later were treated with N9, or PBS, just
before delivering a low-dose viral inoculum (0.05 ID50). As
can be seen in Fig. 3, the low-dose inoculum infected 4 of
32 control mice (exposed twice to PBS), and 1 of 32 posi-
tive control mice (PBS followed 12 hours later by 2% N9
delivered just prior to the inoculum). In contrast, 9 of 32
test mice previously exposed to N9 became infected, even
though in this test group a second dose of N9 was deliv-
ered just prior to the low-dose inoculum to mimic correct
use of a microbicide: (9 of 32 vs 1 of 32; P = 0.013). Thus
a single earlier dose of N9 abolished the transient protec-
tive effect of the subsequent dose of N9 even when used
correctly.
Acute toxic effects of detergents
Detergents can rapidly disrupt the membranes of living
cells exposed on the epithelial surface, and Fig. 4 shows
the effects of a 10-minute exposure to 2% BZK, 2% N9,
and PBS applied to the vagina of progestin-treated mice.
The entire vaginas, opened and flat-mounted, were
stained with the "dead cell" dye YOYO-1 (Molecular
Probes, Eugene, OR) that makes nuclei of cells with dis-
rupted membranes intensely fluorescent. Both detergents
caused large swaths of the epithelial surface to become
intensely fluorescent, regions in which virtually every cell
nucleus became highly fluorescent. In contrast, PBS
caused little detectable damage.
The images graphically reveal the extent of acute damage
caused by these detergents to the living cells on the epithe-
lial surface, unprotected by layers of senescent squamous
cells. Note that the swaths of fluorescent cell nuclei visible
in this figure were in cells located in deeper layers of the
epithelium since the detergents caused the outermost cell
layers to be rapidly shed, as shown above in Fig. 1B and
1C. Also noteworthy is that the detergents failed to enter
several regions of the vaginal surface, as indicated by the
dark, unstained bands. These bands were located on the
interior surfaces of the vaginal rugae (folds); these bands
became fully visible only when the vagina was flattened
(or stretched laterally) sufficiently to spread out the rugae.
Thus the 10-minute exposure to the detergents was not
sufficient for detergents to enter into the rugae of the
vagina. This result was similar to an earlier study using
ethidium homodimer-1 instead of YOYO-1 [23]. In sub-
sequent studies (data not shown), we found that even if a
large ball is placed on the tip of the pipet to help spread
out the rugae, and the pipet is stirred with a variety of
motions, the detergents still fail to enter many of the
rugae. This incomplete "deployment" of vaginal microbi-
cides into the many folds of the vaginal epithelium prob-
ably contributes to the inability to achieve complete
protection in tests of candidate microbicides in animal
models [23]. Moreover, as shown in the following section,
incomplete deployment probably contributes to incom-
plete protection even when microbicide agents are deliv-
Vaginal HSV-2 susceptibility 12 hours after a single applica- tion of candidate microbicides Figure 2
Vaginal HSV-2 susceptibility 12 hours after a single 
application of candidate microbicides. P values (from 
Table 1), determined by Fisher's exact two-sided test as 
described in the caption for Figure 1. n.s. = not significant.
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ered at concentrations much higher than needed to
inactivate pathogens in vitro.
Selectivity index in vivo
Animal models provide the best available method for pre-
dicting whether a candidate microbicide will be suffi-
ciently selective to merit tests in human clinical trials. An
in vivo selectivity index can indicate whether or not a test
agent can provide protection without causing unaccepta-
ble toxic effects.
Fig. 5 illustrates methods for determining a selectivity
index. The upper panel shows a measure of acute toxicity,
the average fluorescence intensity of the entire vagina
stained with YOYO-1 as above (Fig. 4) as a function of the
concentration of the detergent to which the vaginas had
been exposed for 10 minutes. BZK and N9 caused detect-
able increases in fluorescence starting at about 0.05% and
markedly increased fluorescence at 0.2% and above, indi-
cating major regions of epithelial cells had disrupted
membranes. (Other detergents we tested, especially SDS,
an anionic detergent, significantly blocked fluorescence
by YOYO-1, a cationic dye, and hence acute toxicity
caused by these detergents could not be evaluated with
this method. Apparently, despite the extensive and
repeated washing procedure, significant amounts of deter-
gents must have been retained by epithelial cells, perhaps
by being intercalated into cell membranes at concentra-
tions too low to solubilize the membranes but high
enough to interfere with fluorescence of YOYO-1.)
The lower panel in Fig. 5 shows two methods for testing
the protective efficacy of a candidate microbicide in the
mouse HSV model. The "mix externally" method is simi-
lar to cell-based in vitro tests; the viral inoculum is thor-
oughly mixed together with the test agent before  the
mixture is delivered to the vagina. This insures that the
viral inoculum is well exposed to the test agent before the
virions can contact target cells. The "mix in vagina"
method is designed to mimic human use of microbicides;
the candidate microbicide is delivered to the vagina first,
and then the viral inoculum is delivered.
As expected on the basis of cell-based tests, the detergents
were significantly protective in the "mix externally"
method at the minimal concentrations that inactivate
HSV and HIV virions in vitro, ~0.03% [31,33]. At a slightly
higher concentration, ~0.05%, the detergents disrupted
cell membranes in the epithelium, as indicated by
increased YOYO-1 fluorescence of the vagina. In marked
contrast, but also as expected from previous tests in ani-
mal models [26,39,40], in the "mix in vagina" method the
Table 1: 
agent or PBS agent then 0.1 ID50 PBS then 0.1 ID50 PBS then 10 ID50 Relative 
Suscept.
P
12 hours 
earlier
infected inoculated infected inoculated infected inoculated
2 %  N 9 2 94 2 8 4 03 54 02 9 < 0 . 0 0 1
2% C16B2 03 0 4 3 02 52 9 2 9 . 1 < 0 . 0 0 1
2% C14A O 2 54 1 4 3 93 43 7 1 7 . 5 < 0 . 0 0 1
2% BZK 28 40 9 41 37 41 25.5 <0.001
2% SDS 25 37 4 36 34 37 25.0 <0.001
2% CHX 15 45 3 45 35 44 5.4 <0.003
B u f f e r G e l 1 45 2 6 4 63 95 12 . 7 0 . 1 3
2 %  S P S 5 3 9 3 3 43 13 51 . 3 0 . 7
HEC Placebo 3 32 6 30 30 30 0.5 0.3
2% N9 at 
time earlier
5 minutes 8 32 5 32 18 18 1.7 0.5
1 5  m i n u t e s 1 22 8 4 2 72 62 85 . 2 0 . 0 3 7
3 hours 26 39 14 41 23 27 12 0.007
6 hours 15 45 10 43 31 39 2.3 0.35
9 hours 22 38 3 37 35 39 16.6 <0.001
18 hours 9 37 5 34 31 36 2.2 0.4
24 hours 8 29 4 29 24 28 2.4 0.3
2% N9 then 10 ID50
30 seconds 10 18 17 20 0.16 0.07BMC Infectious Diseases 2006, 6:90 http://www.biomedcentral.com/1471-2334/6/90
Page 9 of 16
(page number not for citation purposes)
detergents failed to protect unless delivered at concentra-
tions ~1000-fold higher (~3%). By comparing the upper
and lower panels in Fig. 5 it can be seen that detergents
became acutely toxic at much lower concentrations than
the concentrations needed for significant protection. Most
important, the detergents provided only partial, if any,
protection at 2%, a concentration at which all the deter-
gents markedly increased HSV susceptibility as shown
above in Fig. 2. Thus in this mouse HSV model there was
no concentration at which N9, BZK, C14AO, C16B, and
SDS were protective without causing unacceptable toxic-
ity.
Inflammatory cytokines
Prior to Phase II/III efficacy trials, there is a critical need
for tests that can be performed in Phase I safety trials to
screen out candidates likely to cause unacceptable toxic-
ity. One such screening test is to observe the release of
inflammatory cytokines since inflammatory responses are
likely to increase susceptibility to HIV and other patho-
gens [10,38]. In the mouse HSV model, toxic effects that
increase susceptibility can be directly measured and corre-
lated with releases of inflammatory cytokine responses to
help determine which increases in cytokines correlate best
with increases in susceptibility to HSV infections. There-
fore, in experiments performed in parallel with those
shown in Fig. 2, vaginal lavage samples were obtained 12
hours after a single exposure to the candidate microbi-
cides and analyzed for inflammatory cytokines. The
results are summarized in Fig 6. The detergents were all
tested at a total concentration of 2%, since this was the
minimal concentration at which these detergents pro-
vided partial transient protection. Twelve hours after a sin-
gle application, all detergents tested produced a
significant increase in one or more inflammatory
cytokines: All significantly increased RANTES; N9,
(C14AO+C16B), and SDS significantly increased MIP-1α.
In addition, (C14AO+C16B) significantly increased IL-1β,
and SDS significantly increased KC (murine equivalent of
Il-8). Thus all detergents, as tested here, caused significant
increases both in HSV susceptibility and release of one or
more inflammatory cytokines. Chlorhexidine (CHX)
caused a less marked increase in HSV susceptibility and
only statistically insignificant trends in Il-1β, KC, and
MIP-1α. In contrast to the detergents, BufferGel, SPS, and
the HEC placebo did not significantly increase susceptibil-
ity nor cause a significant release of inflammatory
cytokines. SPS also did not increase susceptibility, but
cytokine proinflammatory results are inconclusive
because unlike the other agents, SPS significantly inter-
fered with the detection of several of the cytokines in the
Bioplex assay.
In summary, by observing a broad range of inflammatory
cytokines there emerged a significant, but non-quantita-
tive correlation between susceptibility-increasing toxicity
and the elevation of inflammatory cytokines. But note
that the time-courses were not well correlated.
Surface distribution of acute toxicity to vaginal epithelium  caused by a 10-minute exposure to detergents Figure 4
Surface distribution of acute toxicity to vaginal epi-
thelium caused by a 10-minute exposure to deter-
gents. Fluorescent intensity of the 'dead cell' dye YOYO-1 is 
proportional to the density of cell nuclei in the epithelium 
whose membranes were disrupted by the detergents. The 
brightly stained swaths of epithelium are regions in which vir-
tually every cell nuclei became stained with YOYO-1. The 
darker regions became visible as the vagina was gently 
stretched and flattened to unfold the rugae.
    1 cm 
2% BZK                                  2% N9                                        PBS 
A single previous exposure to N9 can abolish the brief pro- tective effect of N9 Figure 3
A single previous exposure to N9 can abolish the 
brief protective effect of N9. The low-dose inoculum 
(0.05 ID50) infected only a small fraction of the control group 
treated twice with PBS (first column), and an even smaller 
fraction was infected in the control group treated with 2% 
N9 just before delivering the inoculum (middle column). But 
a significantly larger fraction became infected in the test 
group (right-hand column), revealing that the N9 dose deliv-
ered 12-hour earlier abolished the protective effect of the 
N9 dose delivered just before the inoculum: P = 0.013 by 
Fisher's exact two-sided test.
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Colposcopy fails to detect N9 toxicity that increases 
susceptibility
Any candidate microbicide that causes colposcopically
detectable vaginal toxicity is likely to be screened out prior
to Phase II/III efficacy trials. But it is not known whether
colposcopy can detect all toxic effects that greatly increase
susceptibility to HSV or HIV. Fig. 7 shows high-magnifica-
tion colposcopic images obtained from 10 mice treated
either with a single application of 2% N9 or PBS as a con-
trol. These images were obtained 12 hours after delivering
the detergent (or PBS), the time at which the susceptibil-
ity-increasing toxicity of N9 reaches its peak. Four observ-
ers independently attempted to use colposcopy to
distinguish mice treated with N9 from those treated with
PBS. Attention was focused on detecting erythema, ulcer-
ations, and widened capillaries with more diffuse borders.
Neither by direct visual examination with the colposcope,
nor by careful examination of digitized, greatly enlarged
photographic images, could the observers do better than
chance in distinguishing the N9-exposed mice from the
control mice.
Discussion
Effects of N9 in mice and humans
N9 was thoroughly studied here since it is the microbi-
cidal detergent for which there is the most clinical evi-
dence regarding both its contraceptive efficacy against
sperm [41] and also its failure to provide protection
against STD pathogens some of which, like HIV, are
potently and rapidly inactivated by this detergent [42,43].
N9 is highly potent in vitro against both sperm [34] and
HIV [33](~0.02% inactivates both in seconds), and N9 is
an effective contraceptive. This has led to the conjecture
that despite its toxic effects N9 might protect against HIV
if used correctly every time. However, the results in this
mouse model indicate that even with correct use, N9 may
fail to protect against vaginal HSV infections. For most N9
products it is recommend that coitus take place within 1
hour of application, but as shown in Fig. 1, the duration
of protection in the mouse lasted only ~5 minutes, and
susceptibility increased significantly by 15 minutes, even
though most of the detergent was still present (see [44]).
This suggests that in human use susceptibility might actu-
ally increase soon after the first application of the deter-
gent. Moreover, with repeated use, the prolonged
susceptibility-increasing toxic effects of N9 might abolish
even the brief duration of protection it might otherwise
provide, as shown in Fig 3.
Taken together with the rectal studies by Phillips and col-
leagues [20] the increases in vaginal susceptibility caused
by all five detergents and by CHX cast doubt on the suita-
bility of detergents and surface-active agents for vaginal as
well as rectal protection against HSV. Single applications
of N9 and K-Y® jelly to the mouse uterus cause long-lasting
toxic effects (exfoliation and regeneration still evident
after 48 hours) [9]. CHX, the preservative in K-Y® jelly, not
only increases vaginal susceptibility to HSV but also
causes a major, and long-lasting (3 days) increase in sus-
ceptibility to chlamydia [23]. Since vaginal applications of
the detergents cause significant release of inflammatory
cytokines in mice, rabbits [10] and women [38], these
detergents may also increase susceptibility to HIV infec-
tions (see [10,38]). In contrast, both non-detergent candi-
dates tested here, SPS and BufferGel, when applied at a
protective dose [26,29], did not cause significant toxic
effects.
Epithelial exfoliation and regeneration correlates best 
with HSV susceptibility
We attempted to identify observable toxic effects that
could be used in preclinical and clinical Phase I safety tri-
Acute toxicity, and fraction of mice infected, vs detergent  concentration Figure 5
Acute toxicity, and fraction of mice infected, vs 
detergent concentration. The upper panel shows the 
average fluorescent intensity of the YOYO-1 stained vagina 
as a function of the concentration of detergent to which each 
vagina was exposed for 10 minutes. The lower panel shows 
the fraction of mice infected using two different test meth-
ods: 'mix externally' fully exposes HSV in a high-dose inocu-
lum (10 ID50) to the microbicide prior to inoculation, and 
'mix in vagina' mimics human use of a microbicide, the micro-
bicide is delivered to the vagina before delivering the high-
dose (10 ID50) inoculum. The two detergents in C31G, 
(C14AO+C16B), were combined at equal w/v concentrations 
and plotted at the total detergent concentrations shown.BMC Infectious Diseases 2006, 6:90 http://www.biomedcentral.com/1471-2334/6/90
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als to screen out candidate microbicides that cause suscep-
tibility-increasing toxic effects. These included
observations of epithelial exfoliation (desquamation) and
regeneration, vaginal entry by macrophages, release of
inflammatory cytokines, and colposcopy. The toxic effect
that best correlated with the time-course and duration of
increased HSV susceptibility was the time course of the
changes in thickness of the epithelium. The initial rapid
increase in susceptibility occurred during the initial rapid
exfoliation of epithelial cells (thereby exposing cells
deeper in the epithelium). This result is similar to the
rapid exfoliation caused by N9 applied to the columnar
epithelium of the mouse uterus [9] and mouse rectum
[20]. N9 rapidly increases rectal susceptibility in the
mouse. Based on the dose-response results reported by
Phillips and Zacharopoulos [20], the lowest dose viral
inoculum they used, 5 × 103 PFU, delivered ~0.05 ID50 to
the controls, but acted effectively as ~5 ID50 when deliv-
ered 5 minutes after applying 2 % N9 to the rectum. Thus
2% N9 increased rectal HSV susceptibility by ~100 fold
within 5 minutes of application. The columnar epithe-
lium of the mouse rectum appears to regenerate within ~1
hour [20]. In contrast, the columnar epithelium of the
mouse uterus regenerates in ~72 hours [9]. Since the vag-
inal epithelium became maximally susceptible at ~12
hours, when its cell layers were regenerating, our results
suggest that rectal and uterine susceptibility might
become maximal during the markedly different rates at
which their epithelial cell layers regenerate.
Nectin-1
A possible mechanism for both the early and late phases
of increased susceptibility that occur following epithelial
exfoliation caused by detergents is suggested by the fol-
lowing findings regarding nectin-1, a major cell-surface
entry receptor for HSV: 1) Mice are susceptible to HSV
only during the stages of the estrous cycle when the vagi-
nal epithelium expresses nectin-1, and the most suscepti-
ble stage can be maintained by treatment with Depo-
Provera [45], 2) Incubating HSV with nectin-1 prior to
vaginal inoculation blocked infection [45], 3) In the intact
epithelium nectin-1 is primarily localized in the lateral
surfaces between adjacent epithelial cells, a location
where it is relatively inaccessible to HSV. But upon epithe-
lial disruption by low calcium, nectin-1 migrates from the
lateral surfaces and becomes accessible to HSV on the api-
cal surface, increasing viral entry by HSV [46]. In the
human vagina, nectin-1 is expressed most intensely in
deeper cell layers, the stratum spinosum, the layer of
maturing cells just above the basal cells, and is expressed
closer to the luminal surface during epithelial regenera-
tion in the secretory phase of the cycle [45]. This suggests
that rapid desquamation will rapidly increase access of
HSV to cells whose surfaces have more nectin-1, and also
that during regeneration there will be more nectin-l on the
epithelial surface. Nectin-1 is also heavily expressed on
cell surfaces during epithelial remodelling in the mouse
embryo [46], which again suggests nectin-1 may be heav-
ily expressed during the regeneration of vaginal epithelial
cell layers.
Thus nectin-1 provides a possible mechanism to explain
both the rapid initial increase in susceptibility and for the
later major increase in susceptibility (compare the time-
course for susceptibility, Fig. 1A, with the number of cell
layers, Fig 1B.). The rapid initial increase in susceptibility
was contemporaneous with the exposure of deeper layers
in the epithelium, and the later prolonged increase in sus-
ceptibility occurred contemporaneously with epithelial
regeneration.
Taken together, these results suggest that women may
become more susceptible to HSV within minutes of apply-
ing a microbicide that causes rapid exfoliation of colum-
nar epithelium and may become even more susceptible
throughout the duration of epithelial regeneration.
Human columnar epithelial cells are target cells for HSV,
and in the absence of trauma or open sores or ulcers, the
most susceptible sites are likely to be the columnar epithe-
lial cells in regions of cervical ectopy and in the endocer-
vix. Uterine peristalsis transports vaginal fluids, including
sperm [see [47]] and microbicide gels [48-51], to the
columnar epithelium of upper tract. Thus microbicides
(and pathogens) both contact columnar epithelium of the
upper tract. Even though the vaginal epithelium is pro-
tected by multiple layers of dead and dying squamous
cells, toxic effects of microbicides applied to columnar
epithelium should be carefully considered in the design of
Phase I trials.
Which toxic effects related to HSV susceptibility might 
usefully be monitored in Phase I trials of candidate 
microbicides?
Exfoliation
Monitoring changes in the thickness of the columnar epi-
thelium in women would require biopsy specimens of
ecto- or endocervical tissue taken shortly before and after
exposure to the test agent. However, optical coherence
tomography (OCT, [52]) might provide a non-invasive
method for detecting ecto-cervical exfoliation, and it
might also be possible to detect rapid epithelial exfolia-
tion by collecting lavage or swab samples directly from the
ectocervix and cervical os before and shortly after applying
the candidate microbicide and looking microscopically
for epithelial sheets.
Leukocyte entry
Fichorova, Tucker, and Anderson [38] reported that N9
caused macrophages and neutrophils to enter the human
vaginal lumen in large numbers. Milligan et al, [8]BMC Infectious Diseases 2006, 6:90 http://www.biomedcentral.com/1471-2334/6/90
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reported that both N9 and SDS caused the same to hap-
pen in the mouse vagina, and we confirmed their findings
for N9 and macrophages in this study. Milligan et al. also
reported that two non-detergent candidate microbicides
based on sulfated and sulfonated polymers, T-PSS and
PRO 2000, did not cause significant increases in vaginal
leukocytes even after repeated doses. Thus leukocyte entry
into the lumen is a toxic effect that correlates in this
mouse model with increased HSV susceptibility. How-
ever, unlike changes in epithelial thickness, the time-
course of leukocyte entry does not correlate well with the
increases in susceptibility: During the initial increase in
susceptibility there was no significant increase in the
numbers of leukocytes in the vagina, and at 6 hours, when
the number of macrophages had markedly increased, HSV
susceptibility returned essentially to normal. At 18 hours,
HSV susceptibility again returned to normal but high
numbers of both macrophages and neutrophils persist for
many more hours [8].
Colposcopy
High-magnification colposcopy surprisingly failed to dis-
tinguish between mice exposed 12 hours earlier to N9
from controls treated with PBS. This result does not argue
against performing colposcopic exams, but suggests
instead that this method may not be adequate to detect
certain toxic effects that cause major increases in suscepti-
bility to HSV.
Inflammatory cytokines
Inflammatory cytokines are now being investigated dur-
ing Phase I trials of vaginal microbicide candidates, not
only as sensitive markers for epithelial damage, but also
because they provide insight into important biological
changes that may occur in the vagina as a result of micro-
bicide administration. For example, increased chemokine
concentrations correlate with an influx of immune and
inflammatory cells into the vaginal mucosa. These cells
can play a role in host immune defence, but CD4+
immune cells are also target cells for the HIV-1 virus, and
their increased numbers could promote HIV-1 infection.
Likewise, increased concentrations of Il-1 can activate NF-
KB, an intracellular transcription signal that leads to the
production of other inflammatory cytokines, and can pro-
mote HIV-1 shedding through activation of the HIV-1
LTR.
The results of the present study lend further support for
screening candidate microbicides to insure they do not
cause significant increases in inflammatory cytokines. The
results in mice suggest that several different cytokines, and
durations of exposure, should be investigated since no
single cytokine served as a reliable predictor of significant
toxicity at the time points chosen for this study. For exam-
ple, although the detergents all caused a significant
increase in RANTES, they did so to markedly different
degrees at the 12-hour time point (N9 increased RANTES
~30-fold more than did SDS). Moreover, the major differ-
ences in cytokines released, as shown in Fig. 6, do not cor-
relate with the almost uniform increase in susceptibility
caused by all five detergents as shown in Fig. 3. Note also
that in the mouse, even though a single dose of N9 mark-
edly increased susceptibility to HSV it did not cause a
detectable release of Il-6 and only insignificant trends
occurred in Il-1α, Il-1β, and KC(Il-8), further emphasizing
the lack of obvious correlation between cytokine release
and HSV susceptibility. In the rabbit toxicity model
Fichorova et al [10] found that N9, BZK, and SDS caused
marked, and markedly different, increases in Il-6, IL-1β,
and IL-8 when observed 24 hours after the first, second,
and third daily application. In humans [38] a single appli-
cation of N9 did not cause a detectable increase in any of
the soluble mediators observed in lavage samples
obtained after 12, 36, and 60 hours: IL-1α, IL-1β, IL-8, IL-
1ra, TNF-RI, TNF-RII (but at 12 hours, there was a signifi-
cant decrease in SLPI). However, after 3 daily exposures,
several mediators increased significantly: IL-1α and IL-1β
(at 12, 36, and 60 hours after the last application), IL-8 (at
36 hours), MIP-1β (at 60 hours), TNF-RII (at 36 hours),
neutrophil elastase (at 12 and 36 hours), and SLPI signif-
icantly decreased (at 12, 36 and 60 hours).
Human columnar endocervical epithelial cells are more
sensitive to toxic effects of N-9 in vitro and release more
Inflammatory cytokines 12 hours after a single exposure to  candidate microbicides Figure 6
Inflammatory cytokines 12 hours after a single expo-
sure to candidate microbicides. Geometric means for 
each agent are shown normalized by the results in PBS con-
trols as follows, in ng/ml of lavage fluid: IL-1α, 16; IL-1β, 50; 
KC, 42; MIP-1α, 20; RANTES, 3. Thus N9 increased the con-
centration of RANTES 224-fold, from 3 to 672 ng/ml in lav-
age fluid. (The lavage procedure is estimated to have diluted 
vaginal secretions by 10–50-fold.) (CAO+CB) = 
1%CAO+1%CB = 2% detergent.BMC Infectious Diseases 2006, 6:90 http://www.biomedcentral.com/1471-2334/6/90
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Colposcopic images of mouse vaginas 12 hours after a single exposure to 2% N9, or PBS Figure 7
Colposcopic images of mouse vaginas 12 hours after a single exposure to 2% N9, or PBS. The colposcope (Zeiss 
OPMI 1-SH) was set at maximum magnification (31×) and focused on the vaginal area surrounding the cervix. Column A, 2% 
N9, column B, PBS controls.
A                                            B BMC Infectious Diseases 2006, 6:90 http://www.biomedcentral.com/1471-2334/6/90
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proinflammatory cytokines when damaged than do vagi-
nal epithelial cells[10]. Similarly, in Swiss-Webster mice,
the cervical columnar epithelium is more sensitive to the
toxic effects of detergents than stratified squamous vaginal
epithelium [5,6]. A major difference between vaginal lav-
age samples obtained from humans and the progestin-
treated mice in the present study is the relatively small sur-
face of columnar epithelium in humans that contributes
to the lavage sample. Thus lavage samples from progestin-
treated mice in which the entire vaginal epithelium is cov-
ered with living cells may provide a more sensitive meas-
ure of the effects of candidate microbicides on epithelia
that are not protected by layers of squamous cells. This
may explain why the increases in cytokines caused be sin-
gle applications of the detergents were readily detectable
in the mouse but not in humans.
Finally, our study also highlights the need to test microbi-
cide agents and formulations for inhibitory effects on
cytokine detection. SPS may have produced false negative
readings in the cytokine test because it had a strong inhib-
itory effect on cytokine detection in the Bioplex assy.
Limitations of this study
Even though the mechanism of infection and pathogene-
sis of genital HSV is very similar in both humans and
mice, there is still uncertainty predicting results in
humans based on results in mice.
Pre-treatment with progestin (Depo-Provera) markedly
increases HSV-2 susceptibility in mice, but it has not been
documented whether it has this effect in humans. How-
ever, epithelia in both species that are not protected by a
squamous layer are likely to be more susceptible to HSV.
Effects of formulation were not examined in this study,
and different formulations may have different effects on
toxicity (and efficacy).
Toxic effects of repeated exposures were not examined in
this study. It is apparent that a single exposure to deter-
gents and CHX caused significant toxicity, but other can-
didate microbicides may not cause significant toxicity
unless applied repeatedly.
Results in this mouse/HSV model may not predict the
effect of microbicides on human transmission of HIV,
since there are significant differences in the mechanisms
of transmission. In view of the 20–30 fold increase in HSV
susceptibility a single dose of detergent causes in the
mouse vagina, and the >100 fold increase in susceptibility
N9 causes in the mouse rectum [20], it may be advisable
to develop a primate model that directly detects whether
a candidate microbicide increases susceptibility to SIV or
SHIV since the surrogates now being monitored in animal
models and Phase I trials may not reveal serious altera-
tions in susceptibility.
Conclusion
1. The mouse model for vaginal transmission of HSV-2
can be used to detect toxicities caused by candidate micro-
bicides that increase susceptibility to infection.
2. Detergents applied at a minimally protective dose
caused rapid, prolonged, and major increases in vaginal
HSV-2 susceptibility.
3. SPS and BufferGel are examples of candidate microbi-
cides that protect against HSV infections without causing
susceptibility-increasing toxic effects in this model.
4. In screening for toxic effects of microbicides in Phase I
safety trials, it may be important to monitor a broad range
of inflammatory cytokines vs time, and exfoliation of
columnar epithelium.
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